Oct 22, 2024, 14:57
Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy
Joseph Grossman, Vice President of Early Clinical Development at Agenus, shared a post on LinkedIn:
“The final version of our recent Cancer Discovery paper came out today “Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy”.
I couldn’t be prouder of our team at Agenus, or more excited for the future of oncology.”
Authors: Dhan Chand, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12
Dec 21, 2024, 07:45
Dec 21, 2024, 05:54
Dec 21, 2024, 05:42